Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Asami

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Drugs - Real World Outcomes|February 18, 2021
Relationship of Annual Health Checkups with the Subject's Subsequent Behavior of Cardiovascular Risk Management in a Real-World Setting in Japan: A Retrospective Cohort Study on Changes in Antihypertensive Drug Prescription and Blood Pressure from 2015 to 2017Shingo Higa, Yoichi Ii, Kazutaka Nozawa, et al.
BMJ Open|July 24, 2021
Physician visits and medication prescriptions for major chronic diseases during the COVID-19 pandemic in Japan: retrospective cohort studyItsuki Osawa, Tadahiro Goto, Yuko Asami, et al.
International Clinical Psychopharmacology|October 30, 2015
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in JapanTeruhiko Higuchi, Kunitoshi Kamijima, Kazuyuki Nakagome, et al.
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Drugs - Real World Outcomes|July 2, 2022
The Use of a Network Analysis to Identify Associations and Temporal Patterns Among Non-communicable Diseases in Japan Based on a Large Medical Claims DatabaseShingo Higa, Kazutaka Nozawa, Yusuke Karasawa, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Psychiatry and Clinical Neurosciences|October 22, 2025
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorderTempei Otsubo, Koichiro Watanabe, Takeshi Inoue, et al.
The International Journal of Neuropsychopharmacology|January 17, 2019
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2Ryosuke Arakawa, Per Stenkrona, Akihiro Takano, et al.
Psychiatry and Clinical Neurosciences|January 27, 2026
Response to "Clinical relevance of venlafaxine ER for generalized anxiety disorder"Tempei Otsubo, Koichiro Watanabe, Takeshi Inoue, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Drugs - Real World Outcomes|February 18, 2021
Relationship of Annual Health Checkups with the Subject's Subsequent Behavior of Cardiovascular Risk Management in a Real-World Setting in Japan: A Retrospective Cohort Study on Changes in Antihypertensive Drug Prescription and Blood Pressure from 2015 to 2017Shingo Higa, Yoichi Ii, Kazutaka Nozawa, et al.
BMJ Open|July 24, 2021
Physician visits and medication prescriptions for major chronic diseases during the COVID-19 pandemic in Japan: retrospective cohort studyItsuki Osawa, Tadahiro Goto, Yuko Asami, et al.
International Clinical Psychopharmacology|October 30, 2015
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in JapanTeruhiko Higuchi, Kunitoshi Kamijima, Kazuyuki Nakagome, et al.
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Drugs - Real World Outcomes|July 2, 2022
The Use of a Network Analysis to Identify Associations and Temporal Patterns Among Non-communicable Diseases in Japan Based on a Large Medical Claims DatabaseShingo Higa, Kazutaka Nozawa, Yusuke Karasawa, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Psychiatry and Clinical Neurosciences|October 22, 2025
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorderTempei Otsubo, Koichiro Watanabe, Takeshi Inoue, et al.
The International Journal of Neuropsychopharmacology|January 17, 2019
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2Ryosuke Arakawa, Per Stenkrona, Akihiro Takano, et al.
Psychiatry and Clinical Neurosciences|January 27, 2026
Response to "Clinical relevance of venlafaxine ER for generalized anxiety disorder"Tempei Otsubo, Koichiro Watanabe, Takeshi Inoue, et al.
Pageof 2